Brief: Alector Announces Results From Phase 2 Trial In Individuals With Early Alzheimer’s Disease

Alector

25/11/2024 22:11

Nov 25 (Reuters) - Alector Inc  ALEC.O :
    * ALECTOR ANNOUNCES RESULTS FROM AL002 INVOKE-2 PHASE 2
TRIAL IN
INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE AND PROVIDES BUSINESS
UPDATE
    * ALECTOR INC - AL002 FAILS TO MEET PRIMARY ENDPOINT IN
INVOKE-2
TRIAL
    * ALECTOR INC - TO STOP LONG-TERM EXTENSION STUDY BASED ON
RESULTS
    * ALECTOR INC - TO REDUCE WORKFORCE BY APPROXIMATELY 17%
    * ALECTOR INC - NO SIGNIFICANT EFFECTS ON ALZHEIMER'S
BIOMARKERS
OR AMYLOID LEVELS FROM INVOKE-2 PHASE 2 TRIAL

Source text:  ID:nGNX6VDxQs 
Further company coverage:  ALEC.O 

 ((Reuters.Briefs@thomsonreuters.com;))